Skip to main content

Table 2 Reason for discontinuation and the timing

From: Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

Reason for discontinuationa

Timing of discontinuation, n (%)

Total

Day 1- < 29

Day 29- < 61

Day 61- < 91

Day 91- < 121

Day 121- < 181

Day 181- < 270

Day 270- < 365

Day ≥365

1. Adverse events

43 (21.4)

12 (6.0)

9 (4.5)

4 (2.0)

4 (2.0)

5 (2.5)

7 (3.5)

2 (1.0)

0 (0.0)

2. Worsening of symptoms

14 (7.0)

2 (1.0)

2 (1.0)

1 (0.5)

1 (0.5)

2 (1.0)

3 (1.5)

3 (1.5)

0 (0.0)

3. Improved symptoms

32 (15.9)

4 (2.0)

1 (0.5)

5 (2.5)

4 (2.0)

3 (1.5)

8 (4.0)

6 (3.0)

1 (0.5)

4. Request for discontinuation from patient or family

68 (33.8)

14 (7.0)

13 (6.5)

5 (2.5)

5 (2.5)

7 (3.5)

13 (6.5)

9 (4.5)

2 (1.0)

5.Transfer to another hospital

21 (10.4)

2 (1.0)

4 (2.0)

0 (0.0)

0 (0.0)

7 (3.5)

4 (2.0)

4 (2.0)

0 (0.0)

6. Lost to follow-up

38 (18.9)

7 (3.5)

7 (3.5)

3 (1.5)

4 (2.0)

5 (2.5)

7 (3.5)

5 (2.5)

0 (0.0)

7. Other

15 (7.5)

2 (1.0)

1 (0.5)

0 (0.0)

2 (1.0)

7 (3.5)

2 (1.0)

0 (0.0)

1 (0.5)

Totalb

201 (100.0)

37 (18.4)

34 (16.9)

16 (8.0)

17 (8.5)

30 (14.9)

39 (19.4)

24 (11.9)

4 (2.0)

  1. a: Multiple responses were allowed in a patient. Concurrent reasons are: 3 and 4 (n = 9), 1 and 4 (n = 8), 1 and 2 (n = 4), 1 and 7 (n = 3), 4 and 7 (n = 2), 2 and 4 (n = 1), 1 and 6 (n = 1), 1, 2, and 4 (n = 1)
  2. b: If more than one reason for discontinuation was observed in a patient, the data were summarized as 1 patient